- Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years
- Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids
- Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect
Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017 Marijuana Business Conference & Expo (MJBizCon) in Las Vegas, Lexaria’s chairman and CEO Chris Bunka offered some thoughts on the future of cannabis during an interview with The Street at the LD Micro conference in Los Angeles last week.
“The market potential of cannabis is really exploding worldwide, it’s not just an American phenomenon, it’s happening in Canada, Mexico, Germany, Australia, all over the world,” Bunka told The Street’s Kinsey Grant (http://cnw.fm/2HXqK). “It’s expected to be in the $30-$50 billion range in the next three to four years … and growing very, very rapidly.”
Lexaria BioScience’ss groundbreaking technology is specifically created for the delivery of APIs, or active pharmaceutical ingredients, found in cannabis, vitamins, non-steroidal anti-inflammatory drugs and, even, nicotine.
“We effectively help CBDs get into the bloodstream more rapidly and more efficiently than they otherwise can,” Bunka told Grant in the interview. “We’ve developed this technology – we’re really a research and development company – and we license it off to other companies that have expertise in developing consumer products or cannabis-related products, and they utilize our technology to make those products better.”
The company’s DehydraTECH™ proprietary technology is not only cost effective, it has been proven to enhance the performance of beneficial compounds in ingestible products (http://cnw.fm/5g4QZ). An edible cannabinoid product, for instance, becomes better tasting, better smelling, has better bioavailability and absorption, and lasts longer when Lexaria’s patented delivery technology is utilized. Because Lexaria’s technology enables or works with all ingested forms of cannabinoids, the company is seen as an attractive partner with various biotech companies conducting cannabinoid research and development, and it could be an equally attractive acquisition target (http://cnw.fm/qHA1h).
Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria additional future growth potential.
For more information, visit the company’s website at www.LexariaEnergy.com
More from CannabisNewsWire
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
